May 21, 2018
Innovations are transforming healthcare, but these innovations have to align with business models and they still have to be validated before they can improve care delivery, explained Harlan Krumholz, MD, SM, Harold H. Hines Jr professor of Medicine and Epidemiology and Public Health, Yale School of Medicine, and director, Center for Outcomes Research and Evaluation, Yale-New Haven Hospital.
May 09, 2018
In an attempt to distance itself from the controversy it faced over steep drug price increases, Valeant Pharmaceuticals will change its name to Bausch Health Companies; medical bills are dragging down some people's credit scores; Minnesota governor warns Republican state lawmakers against trying to block expansion of MinnesotaCare.
Sanofi, Regeneron to Cut Praluent Prices Under Exclusive Express Scripts Deal That Ends Prior Approval Delays
May 01, 2018
While precise pricing information was not released, net pricing will be within the cost-effective ranges set by the Institute for Clinical and Economic Review.
April 25, 2018
Takeda Pharmaceutical has increased its bid to purchase Shire Plc to $64 billion; a process for reviewing drug patents has been ruled constitutional by the Supreme Court of the United States; at the University of California, Los Angeles, an “unspoken taboo” against reusing transplanted kidneys is being challenged.
April 24, 2018
The confirmation hearing for the president's new pick to run the Department of Veterans Affairs (VA) is being postponed; hospital profits are at 10-year low; new recommendations re-imagine postpartum care.
April 24, 2018
David Blumenthal, MD, MPP, president of The Commonwealth Fund, discusses the role of mergers and acquisitions in delivering affordable, high-quality care.
March 23, 2018
Ed F. Haislmaier, the Preston A. Wells Jr senior research fellow at the Institute for Family Community, and Opportunity at The Heritage Foundation, talks about the impact of new business partnerships on healthcare costs.
March 08, 2018
Cigna has announced that it will acquire Express Scripts in a $67 billion deal. The deal brings health benefits and pharmacy benefits under the same roof and is the latest in a string of acquisitions and mergers as the industry attempts to address health costs.